Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96weeks

BackgroundPatients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles.AimTo evaluate how these changes affect cardiovascular risk.MethodsThis pooled analysis, based on two large prospective studies, evaluat...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2024-01, Vol.59 (2), p.217-229
Main Authors: Fung, Scott K, Pan, Calvin Q, Grace Lai‐Hung Wong, Wai‐Kay Seto, Ahn, Sang Hoon, Chi‐Yi Chen, Hie‐Won L Hann, Jablkowski, Maciej S, Yoon Jun Kim, Yurdaydin, Cihan, Cheng‐Yuan Peng, Nguyen, Tuan, Yatsuhashi, Hiroshi, Flaherty, John F, Yee, Leland J, Abramov, Frida, Wang, Hongyuan, Abdurakhmanov, Dzhamal, Young‐Suk Lim, Buti, Maria
Format: Article
Language:English
Subjects:
Arteriosclerosis
Atherosclerosis
Blood pressure
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Fasting
Hepatitis
Hepatitis B
High density lipoprotein
Lipids
Patients
Tenofovir
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundPatients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles.AimTo evaluate how these changes affect cardiovascular risk.MethodsThis pooled analysis, based on two large prospective studies, evaluated fasting lipid profiles of patients with CHB who were treated with TAF 25 mg/day or TDF 300 mg/day for 96 weeks. Patients who fulfilled the American College of Cardiology criteria (age 40–79 years, high‐density lipoprotein [HDL] 20–100 mg/dL, total cholesterol [TC] 130–320 mg/dL and systolic blood pressure 90–200 mmHg) required to assess 10‐year atherosclerotic cardiovascular disease (ASCVD) risk with baseline lipid data and at least one post‐baseline measurement were included in the ASCVD‐risk population. The 10‐year ASCVD risk was calculated for patients in this population, and changes from baseline to Week 96 were assessed using intermediate‐ (≥7.5%) and high‐risk (≥20%) cut‐offs.ResultsAmong 1632 patients, 620 (38%) met the criteria for the ASCVD‐risk population. At Week 96, fasting levels of all lipids, except TC:HDL ratio, were lower with TDF than TAF. No significant increase was observed in overall ASCVD risk or in any ASCVD‐risk categories during the 96‐week treatment period compared with baseline. A similar proportion of patients in the TAF and TDF treatment groups (1.3% and 2.3%, respectively; p = 0.34) reported cardiovascular events.ConclusionDespite on‐treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks.
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.17764